Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 514-516

  Ferrajoli, Alessandra ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CLL; GM CSF; Rituximab; Treatment

Indexed keywords

BETA 2 MICROGLOBULIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BONE PAIN; CANCER REGRESSION; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; HIGH RISK PATIENT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; VIDARABINE;

EID: 67650879316     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902763541     Document Type: Article

References (9)

1. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J. Neidhart, J. A. et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, pp. 2188-2195.
2. Venugopal, P., Sivaraman, S., Huang, X. K., Nayini, J., Gregory, S. A. and Preisler, H. D. (2000) Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res, 24, pp. 411-415.
3. Voso, M. T., Pantel, G., Rutella, S., Weis, M., D'Alo, F. Urbano, R. et al. (2002) Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica, 87, pp. 918-925.
4. Liu, N. S., Grimm, E., Poindexter, N., Rodriguez, M. A., Hagemeister, F. B. Pro, B. et al. (2003) Antibody dependent cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF. Blood, 102, p. 411a.
5. Huhn, D., von Schilling, C., Wilhelm, M., Ho, A. D., Hallek, M. Kuse, R. et al. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, pp. 1326-1331.
6. Itala, M., Geisler, C. H., Kimby, E., Juvonen, E., Tjonnfjord, G. Karlsson, K. et al. (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur J Haematol, 69, pp. 129-134.
7. Hainsworth, J. D., Litchy, S., Barton, J. H., Houston, G. A., Hermann, R. C. Bradof, J. E. et al. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol, 21, pp. 1746-1751.
8. O'Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J. Cortes, J. et al. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol, 19, pp. 2165-2170.
9. Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A. Park, K. et al. (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol, 19, pp. 2153-2164.